2024
A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy
Miao Y, Niu L, Lv X, Zhang Q, Xiao Z, Ji Z, Chen L, Liu Y, Liu N, Zhu J, Yang Y, Chen Q. A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy. Advanced Materials 2024, 36: e2410715. PMID: 39210649, DOI: 10.1002/adma.202410715.Peer-Reviewed Original ResearchCancer immunotherapyMaturation of antigen-presenting cellsVaccine carriersImmune checkpoint blockade therapyAntigen-specific immune responsesInhibition of tumor growthCheckpoint blockade therapyEnhanced cancer immunotherapyAntigen-presenting cellsVaccine delivery technologiesB16-OVABlockade therapyImmune activationTumor modelTumor growthAntigen loadNanovaccineImmune responseMeticulous screeningAntigenic peptidesImmunostimulatory characteristicsChain ratioDelivery technologiesImmunotherapyIn vivoAn emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria
Chen L, Kang Z, Shen J, Zhao R, Miao Y, Zhang L, Zheng Z, Zhang Z, Liu N, Wang C, Fang H, Zhou J, Wang Y, Liu Z, Yang Y, Chen Q. An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria. Science Bulletin 2024, 69: 2565-2579. PMID: 38918142, DOI: 10.1016/j.scib.2024.06.016.Peer-Reviewed Original ResearchConceptsF. nucleatumColorectal cancerEffective antigen presentationEnhance chemotherapy efficacyT cell activationReduce cancer metastasisPoor treatment outcomesIncreased cancer cell growthCancer cell growthOral anaerobesDendritic cellsFusobacterium nucleatumChemotherapy efficacyAntitumor effectAntigen presentationBiomimetic nanovaccinesEnhanced chemotherapyNanovaccineAlum adjuvantCpG oligonucleotidesTreatment outcomesImmune responseImmune progressionTherapeutic effectVaccine effectivenessProgrammable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy
Wang C, Chen L, Zhu J, Wang C, Li M, Miao Y, Liu N, Ji Z, Pan F, Liu Y, Zhu J, Yang Y, Chen Q. Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202316092.Peer-Reviewed Original ResearchSonodynamic therapyAntitumor immune responseTumor-associated antigensImmune memory responsePrevent tumor recurrenceInhibit tumor metastasisOrthotopic colorectal tumorsAbscopal effectTumor recurrenceEffective sonodynamic therapyTumor siteNano-sonosensitizersTumor hypoxiaPathogen-associated molecular patternsColorectal tumorsMemory responsesTherapeutic delivery systemsTumor metastasisImmune responseTumorLive biotherapeuticsMetastasisBacterial pathogen-associated molecular patternsMolecular patternsOverexpressing catalaseMinimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy
Niu L, Miao Y, Cao Z, Wei T, Zhu J, Li M, Bai B, Chen L, Liu N, Pan F, Zhu J, Wang C, Yang Y, Chen Q. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy. ACS Nano 2024, 18: 3349-3361. PMID: 38230639, DOI: 10.1021/acsnano.3c10174.Peer-Reviewed Original ResearchConceptsTumor-specific immune responsesBone marrow-derived dendritic cellsCancer immunotherapyDendritic cellsCancer vaccinesActivate tumor-specific immune responsesCell death protein ligand 1Mouse bone marrow-derived dendritic cellsImmune responseMarrow-derived dendritic cellsAnti-PD-L1Codelivery of antigenEffective cancer vaccinesPre-existing tumorsActivated dendritic cellsAntigen cross-presentationDC maturationCross-presentationTumor modelProphylactic efficacyNanovaccineImmune effectsImmunotherapyPeptide antigensCancer
2023
A coordinative dendrimer-based nanovaccine for cancer treatment
Cao Z, Ren L, Niu L, Zhao R, Liu N, Zhuang Q, Pan F, Liu Z, Cheng Y, Yang Y, Chen Q. A coordinative dendrimer-based nanovaccine for cancer treatment. Matter 2023, 6: 3574-3597. DOI: 10.1016/j.matt.2023.08.001.Peer-Reviewed Original ResearchCancer vaccinesCancer immunotherapyDendritic cellsField of cancer immunotherapyTumor-specific immune responsesEffective cancer immunotherapyAnti-PD-L1Efficient antigen cross-presentationAntigen cross-presentationCGAS-STING pathwayCross-presentationImmune responseCancer cellsTherapeutic effectCancer treatmentCancerCGAS-STINGImmunotherapyVaccinePeptide carrierCellsNanovaccineNeoantigensPeptidePatients